Abstract:Duchenne muscular dystrophy (DMD) results from mutations in the largest known gene, dystrophin. Gene therapy for DMD will require methods to systemically deliver a therapeutic dystrophin gene to widely distributed muscles. Recent observations indicating that vascularly transplanted adult stem cells can home and become muscle cells in an appropriate micro-environment has suggested one possible method for delivering genes to muscle. A smaller, easily traceable, and functional dystrophin would facilitate experiments aimed at improving ex vivo cell-based strategies. We previously found that large portions of the dystrophin central rod domain (Hinge 2 to Repeat 19) and the C-terminal domain (encoded on exons 71 to Exon 78) are not essential for the full function of dystrophin, as assayed by the ability to prevent and partially reverse morphological and fucnional abnormalities in mdx mouse skeletal muscles. Here, we engineered a 5.7-kb MiniDys-eGFP fusion gene by replacing the C-terminal domain of mini-dystrophin (DH2-R19) with an enhanced green fluorescence gene coding sequence and by trimming down the size of 5' and 3' UTR of dystrophin. This fusion gene can be inserted into lentiviral vectors and efficiently delivered into a variety of cell types in vitro. This MiniDys-eGFP fusion protein was found to fully prevent dystrophy of multiple skeletal muscles in transgenic mdx mice carrying the fusion gene under the control of the human a-skeletal actin (HSA) gene promoter. This green fusion protein was easily observed by fluorescence microscopy on the sarcolemma of skeletal muscle fibers of the transgenic mdx mice. Furthermore, donor-derived GFP-positive myofibers were detected in mdx recipient muscles transplanted with either whole bone marrow cells or primary myoblasts isolated from the MiniDys-eGFP transgenic mice. These data indicate that the smaller, easily traceable, and functional MiniDys-eGFP will be useful for developing ex vivo cell-based gene therapies for DMD.

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-associated virus for the treatment of muscle diseases: toward clinical trials

Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials

Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

Design of Trans-Splicing Adeno-Associated Viral Vectors for Duchenne Muscular Dystrophy Gene Therapy.

Engineering adeno-associated virus vectors for gene therapy

rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates

Systemic delivery of genes to striated muscles using adeno-associated viral vectors

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy

Development of a Gene Therapy for Fabry Disease Using Adeno-Associated Viral Vector Mediated Gene Transfer

Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases

AAV-mediated gene therapy to the isolated limb in rhesus macaques

242. A Novel MiniDys-eGFP Fusion Gene for Developing Cell-Based Therapies of Duchenne Muscular Dystrophy

Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.

Recombinant adeno-associated virus as delivery vector for gene therapy--a review.

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy